Oxular Announces the Appointment of Dr. Friedrich Asmus as Chief Medical Officer

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Oxular Limited, a leading retinal therapeutics development company, today announces it has appointed Dr. Friedrich (Fritz) Asmus as Chief Medical Officer. Dr. Asmus will lead all medical, clinical, and regulatory functions to further the Company’s lead asset, OXU–001, for the treatment of diabetic macular edema (DME), and to accelerate the development of its early-product pipeline.

Dr. Asmus is a board-certified neurologist and pharmacist and, for more than 10 years, has successfully headed clinical development programs in the US, Europe, and Asia. Fritz was a key strategic leader in the successful development of alfibercept and other ophthalmic therapies at Bayer Pharma, including indications for DME, diabetic retinopathy, and retinal vein occlusions. Fritz also led development activities for rare ophthalmic diseases at ProQR Therapeutics and jCyte, where he headed the intravitreal oligonucleotide program for genetic forms of Retinitis pigmentosa (RP) and clinical development for an intravitreal cell therapy program for RP, respectively. Fritz holds a private lectureship for Neurology at the University Hospital of Tuebingen, Germany, where he was also Deputy Chair of the Department of General Neurology. He has published over 50 peer-reviewed articles in ophthalmology and neurology.

Prof. Marc D. de Smet, who has served as Oxular’s Chief Medical Officer in a part time capacity alongside his private clinical practice, will continue working with the Company as Senior Medical Advisor, bringing his world-leading retinal expertise to the ongoing development of the Company’s programs and technology.

Fritz’s appointment follows Oxular’s successful completion of a $37m financing in March 2021 and is a significant milestone in building the Oxular team to support future clinical trials and expanded R&D activities. Fritz joins as Oxular prepares to initiate human clinical trials for its lead asset, OXU-001, an extended-duration treatment for DME.

Thomas Cavanagh, Chief Executive Officer of Oxular, commented: “We are pleased to have Fritz join our leadership team, especially at this critical time when we are readying OXU–001 to begin human clinical studies and accelerating further the development of our highly differentiated product pipeline. Fritz’s depth of knowledge and experience in back-of-eye therapies will be highly advantageous in delivering on our pipeline’s promise of effective and longer-lasting treatments that offer patients truly life-changing solutions to their unmet needs.

“I’d like to acknowledge and thank Prof. de Smet for his incredible work over the last three years. The Company would not have advanced this far without his advice and expertise, and I look forward to continuing to work with Marc as the Company’s programs begin human clinical trials and as we expand use of Oxulumis™ (suprachoroidal space, illuminated microcatheter) to deliver important treatments for sight threatening diseases.”

Dr. Friedrich Asmus, Chief Medical Officer of Oxular, commented: “I have been really impressed with the work scientists at Oxular have delivered in supporting an expanded role of drug delivery to the suprachoroidal space. It is a great privilege to be part of Oxular’s team, driving outstanding innovation to establish an entire product platform of suprachoroidal therapies for areas of high unmet patient need in common and ultra-rare ophthalmic indications.”

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles

Join our list

Subscribe to our mailing list and receive an end-of-week recap news and updates delivered right to your email inbox.